Advocacy & Public Policy
Resources from the 黑料正能量 Association (AHA) on advocacy and public policy health care issues.
AHA letter to Representative Brad Schneider expressing support for legislation, H.R. 3414, the Opioid Workforce Act of 2019,
On Oct. 24, 2018, President Trump signed into law the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018 (P.L. 115-271).
The 黑料正能量 Association鈥檚 2019 Public Policy Advocacy Agenda seeks to continue to positively influence the public policy environment for patients, communities and the health care field. We will work hand in hand with our members; the state, regional and metropolitan hospital associations鈥
Sens. Amy Klobuchar, D-Minn., Susan Collins, R-Maine, Jacky Rosen, D-Nev., and Chuck Grassley, R-Iowa, yesterday introduced AHA-supported legislation (S. 948) to improve and extend the Conrad State 30 program until 2021.
Rick Pollack
AHA letter to Representative Terri Sewell expressing support for the the Resident Physician Shortage Reduction Act of 2019 (H.R. 1763).
Patients should be confident in knowing that their hospital is their lifeline to access care in their community. The cuts proposed today raise serious concerns about how hospitals and health systems can ensure they serve as the safety net for their patients.
The Food and Drug Administration鈥檚 draft guidance on blood glucose monitoring test systems for prescription point-of-care use would appropriately improve the safety and efficacy of the devices while recognizing their vital role in hospitals and health systems, AHA said in comments submitted鈥
The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs.